Tempest Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
TPST$0.37+3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(26,262) | $(41,843) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 266 | 389 |
| Stock-based compensation expense | 3,118 | 5,303 |
| Noncash lease expense | 1,103 | 1,309 |
| Noncash interest and other expense, net | 85 | 202 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 615 | (110) |
| Accounts payable | (1,412) | 1,605 |
| Accrued expenses and other liabilities | (3,404) | 1,273 |
| Interest payable | (59) | (54) |
| Operating lease liabilities | (870) | (1,101) |
| Cash used in operating activities | (26,820) | (33,027) |
| Investing activities: | ||
| Purchase of property and equipment | — | (435) |
| Cash used in investing activities | — | (435) |
| Financing activities: | ||
| Proceeds from the issuance of common stock, net of issuance costs | 6,045 | 28,591 |
| Proceeds from the issuance of pre-funded warrants, net of issuance costs | 3,309 | — |
| Proceeds from the issuance of common stock warrants, net of issuance costs | 1,284 | — |
| Repayment of loan | (6,426) | (4,398) |
| Proceeds from the issuance of common stock under equity plan awards | 47 | 307 |
| Cash provided by financing activities | 4,259 | 24,500 |
| Net increase in cash and cash equivalents | (22,561) | (8,962) |
| Cash, cash equivalents and restricted cash at beginning of period | 30,711 | 39,673 |
| Cash, cash equivalents and restricted cash at end of period | 8,150 | 30,711 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $192 | $1,177 |
| Cash paid for business taxes | $43 | $54 |
| Non-cash investing activities: Property and equipment in accounts payable | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.